Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Longboard Pharmaceuticals

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LP352

            Therapeutic Area: Neurology Product Name: LP352

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Arena Pharmaceuticals

            Deal Size: $56.0 million Upfront Cash: Undisclosed

            Deal Type: Financing October 28, 2020

            Details:

            Proceeds from the financing will be used to support the development of LP352 for treatment-resistant developmental and epileptic encephalopathies, and preclinical programs relating to LP143 and LP659 for the potential treatment of microglial neuroinflammatory diseases.